Evidence map›Paper›PMID 20556744›Full record

ArticleThe Journal of pathology2010

Gene amplification of the transcription factor DP1 and CTNND1 in human lung cancer.

Sandra D Castillo, Barbara Angulo, Ana Suarez-Gauthier, Lorenzo Melchor, Pedro P Medina, Lydia Sanchez-Verde, Juan Torres-Lanzas, Guillermo Pita, Javier Benitez, Montse Sanchez-Cespedes

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. MAX mutant small-cell lung cancers exhibit impaired activities of MGA-dependent noncanonical polycomb repressive complex.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  7. Article
  8. Article
  9. Novel somatic alterations underlie Chinese papillary thyroid carcinoma.Cancer biomarkers : section A of Disease markers · 2020
    Article
  10. Article
  11. Article
  12. Role of ARPC2 in Human Gastric Cancer.Mediators of inflammation · 2017
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Sandra D CastilloGenes and Cancer Group, Programa de Epigenetica y Biologia del Cancer (PEBC), Institut d'Investigacions Biomediques Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Barbara Angulo
Ana Suarez-Gauthier
Lorenzo Melchor
Pedro P Medina
Lydia Sanchez-Verde
Juan Torres-Lanzas
Guillermo Pita
Javier Benitez
Montse Sanchez-Cespedes
Spanish National Cancer Research Centre · ESInstitut d'Investigació Biomédica de Bellvitge · ESHospital Universitario Virgen de la Arrixaca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The search for novel oncogenes is important because they could be the target of future specific anticancer therapies. In the present paper we report the identification of novel amplified genes in lung cancer by means of global gene expression analysis. To screen for amplicons, we aligned the gene expression data according to the position of transcripts in the human genome and searched for clusters of over-expressed genes. We found several clusters with gene over-expression, suggesting an underlying genomic amplification. FISH and microarray analysis for DNA copy number in two clusters, at chromosomes 11q12 and 13q34, confirmed the presence of amplifications spanning about 0.4 and 1 Mb for 11q12 and 13q34, respectively. Amplification at these regions each occurred at a frequency of 3%. Moreover, quantitative RT-PCR of each individual transcript within the amplicons allowed us to verify the increased in gene expression of several genes. The p120ctn and DP1 proteins, encoded by two candidate oncogenes, CTNND1 and TFDP1, at 11q12 and 13q amplicons, respectively, showed very strong immunostaining in lung tumours with gene amplification. We then focused on the 13q34 amplicon and in the TFDP1 candidate oncogene. To further determine the oncogenic properties of DP1, we searched for lung cancer cell lines carrying TFDP1 amplification. Depletion of TFDP1 expression by small interference RNA in a lung cancer cell line (HCC33) with TFDP1 amplification and protein over-expression reduced cell viability by 50%. In conclusion, we report the identification of two novel amplicons, at 13q34 and 11q12, each occurring at a frequency of 3% of non-small cell lung cancers. TFDP1, which encodes the E2F-associated transcription factor DP1 is a candidate oncogene at 13q34. The data discussed in this publication have been deposited in NCBIs Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO Series Accession No. GSE21168.

Indexed as

Carcinoma, Non-Small-Cell LungCateninsCell SurvivalChromosomes, Human, Pair 11Chromosomes, Human, Pair 13Cluster AnalysisDelta CateninGene AmplificationGene Expression Regulation, NeoplasticGenes, NeoplasmHumansLung NeoplasmsMutationNeoplasm ProteinsRNA InterferenceRNA, Small InterferingCateninsCTNND1 protein, humanDelta CateninNeoplasm ProteinsRNA, Small InterferingTranscription Factor DP1

Identifiers

PMID20556744
OpenAlexW2027417241

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.